CAMBRIDGE, Mass.--(BUSINESS WIRE)--April 3, 2006--Curis, Inc. (NASDAQ: CRIS - News), a therapeutic drug development company, today announced the presentation of data at the 97th Annual Meeting of the American Association for Cancer Research (AACR). The preclinical animal model data presented suggested that a Hedgehog antagonist inhibited the growth of tumors in pancreatic cancer and small cell lung cancer. The data are being presented by a Genentech, Inc. researcher as part of the "New Horizons in the Development of Targeted Therapies for the Treatment of Cancer" Symposium. These data were generated as part of Curis' ongoing collaboration with Genentech to develop systemically administered Hedgehog small molecule antagonists for the potential treatment of solid tumors.
